Pemigatinib is something that keeps cholangiocarcinoma at bay, particularly in cases involving FGFR2 fusions. And it does this by interrupting FGFR signaling. They’ve got the tablets in different strengths: 4.5 mg, 9 mg, or 13.5 mg.
The suggestion is to take that 13.5 mg pill every single day for two weeks at a time, and then have a break for a week. One bottle has 14 tabs for you.
